Novel PCSK9 Inhibitor Recaticimab Lowers LDL-C in Adult Heterozygous Familial Hypercholesterolemia
September 12th 2025Recaticimab significantly lowered low-density lipoprotein cholesterol (LDL-C) levels, showing promise in becoming a future proprotein convertase subtilisin/kexin type 9 (PCSK9) option for cholesterol reduction.
Read More
Expanding the Pharmacist’s Role in Myelofibrosis: Education, Adherence, and Access
Pharmacists play a crucial role in managing myelofibrosis, enhancing patient education, adherence, and financial navigation for optimal care.
Watch
Decoding Most Favored Nation: Expert Insights on the Impacts to Patients, Pharma, and Innovation
A panel of 4 experts discussed the most favored nation (MFN) initiative and its impacts on research and development, market and payer distributions, and pharmacists and patients.
Read More
Novel Conditioning Strategies Emerge in Gene Therapy, Leaving Busulfan—and Toxicities—Behind
September 12th 2025Speakers at an ASTCT Gene Therapy Summit highlighted novel conditioning approaches without the use of busulfan, which can cause toxic effects in patients with hematologic malignancies.
Read More